• Novobiocin: Applied Workflows for Antiparasitic and Antivira

  2026-06-28

  Novobiocin’s dual action as an aminocoumarin antibiotic and Hsp90 inhibitor enables streamlined experimental workflows across antibacterial, antiparasitic, and antiviral domains. This guide delivers protocol-ready insights, advanced troubleshooting, and data-driven strategies to help researchers leverage Novobiocin for next-generation infectious disease studies.

• BMS 599626 Dihydrochloride: EGFR and ErbB2 Inhibitor Workflo

  2026-06-27

  BMS 599626 dihydrochloride empowers cancer research with its potent, nanomolar inhibition of EGFR and ErbB2, offering precise control of oncogenic signaling in breast and lung cancer models. This guide details optimized protocols, advanced applications, and troubleshooting strategies to maximize experimental impact with APExBIO’s trusted reagent.

• Molnupiravir Suppresses Bourbon Virus Pathology in Mouse Mod

  2026-06-26

  This study demonstrates that molnupiravir, a broad-spectrum nucleoside analogue, robustly inhibits Bourbon virus replication and associated pathology in mice. The work identifies molnupiravir as a leading candidate for preclinical development against emerging tick-borne RNA viruses that currently lack approved antiviral therapies.

• Cyclic di-GMP Regulates Biofilm Genome Stability and Persist

  2026-06-26

  Liao et al. (2024) identify cyclic di-GMP as a small-molecule antitoxin controlling both genome integrity and antibiotic persistence in bacterial biofilms. This mechanistic advance reframes how toxin-antitoxin systems contribute to biofilm resilience and offers new directions for infection research.

• Pronase E Protease Mixture: Precision Protein Digestion Work

  2026-06-25

  Pronase E, a high-activity protease mixture from APExBIO, unlocks reproducible protein and peptide mapping for advanced proteomics and translational oncology workflows. Discover how its broad substrate range, protocol versatility, and troubleshooting strategies empower rigorous sample preparation and mechanistic studies—especially in complex contexts like ferroptosis research.

• PPM-18 and the NF-κB/iNOS Axis: Precision Tools for Advanced

  2026-06-25

  Explore how PPM-18, a potent N-(1,4-dihydro-1,4-dioxo-2-naphthalenyl)-benzamide, enables precise modulation of iNOS and NF-κB signaling in inflammation and sepsis models. This article delivers a unique, assay-focused analysis with actionable insights for translational researchers.

• YTHDF2 Inhibition Boosts Protein Synthesis and Memory in Mic

  2026-06-24

  This study demonstrates that forebrain-specific knockout of YTHDF2, a key m6A reader protein, enhances synaptic protein synthesis and hippocampus-dependent memory in mice. These findings clarify the role of m6A-mediated mRNA degradation in neuroplasticity and suggest new molecular targets for cognitive intervention.

• Pertussis Toxin in Immune Modulation: Protocols & Troublesho

  2026-06-23

  Pertussis toxin is a gold-standard AB5-type protein exotoxin used for precise immune response modulation, particularly in dissecting cAMP signaling and T helper cell differentiation. This guide unpacks applied workflows, troubleshooting strategies, and the translational impact of using high-purity APExBIO Pertussis toxin in immunological and vascular research.

• Metal-Ion Chelating L-Phe Nanostructures Enhance Tumor Immun

  2026-06-23

  This study demonstrates that metal-ion-chelating L-phenylalanine nanostructures, when combined with short-term starvation, remodel the immunosuppressive tumor microenvironment and sensitize breast tumors to immune checkpoint blockade. The work introduces a mechanism by which nanostructures modulate dendritic cell electrophysiology, offering a new strategy for improving immunotherapy outcomes.

• NMDAR-Dependent Maturation of PV Interneuron GABA Release Me

  2026-06-22

  This study uncovers how NMDA receptor (NMDAR) signaling in developing neocortical parvalbumin (PV) interneurons orchestrates the recruitment of Cav2.1 channels for synchronized GABA release. These findings clarify the cellular basis of inhibition deficits in schizophrenia models and highlight the specificity of NMDAR-Cav2.1 coupling for interneuron maturation and inhibitory circuit function.

• IWR-1-endo: Mechanistic Insights and Assay Innovation in Wnt

  2026-06-22

  Explore the advanced mechanisms by which IWR-1-endo, a potent Wnt signaling inhibitor, drives innovation in colorectal cancer and regenerative biology research. This article uniquely integrates mechanistic depth with assay design insights, providing an authoritative resource for scientists seeking optimized applications.

• VX-702: Precision p38α MAPK Inhibition and Dephosphorylation

  2026-06-21

  Explore how VX-702, a selective p38α MAPK inhibitor, uniquely modulates kinase dephosphorylation and cytokine suppression. This article provides advanced insights for inflammation and myocardial injury research, distinguishing itself with a focus on structural and conformational assay implications.

• AR Heterogeneity Drives Divergent Prostate Cancer Therapy Re

  2026-06-20

  This study illuminates how androgen receptor (AR) expression heterogeneity in prostate cancer underlies distinct responses to castration and enzalutamide therapies. By dissecting AR+/hi and AR−/lo cell populations, the research uncovers critical molecular pathways and therapeutic vulnerabilities, with implications for overcoming resistance in advanced prostate cancer.

• USP36–Snail1 Axis Drives Ribosome Biogenesis and Tumor Survi

  2026-06-19

  This study uncovers how USP36 stabilizes nucleolar Snail1 to promote ribosome biogenesis and enhance cancer cell survival under ribotoxic stress. The findings provide a mechanistic rationale for targeting the JNK–USP36–Snail1 pathway to overcome resistance in solid tumor therapies based on ribosome inhibition.

• Balsalazide Disodium: Targeted 5-ASA Prodrug for Ulcerative

  2026-06-19

  The reference study systematically evaluates balsalazide disodium, a targeted prodrug of 5-aminosalicylic acid, for its efficacy and safety in the treatment of active ulcerative colitis. The findings highlight its unique colonic activation, rapid induction of remission, and favorable tolerability, informing both clinical and preclinical inflammation research.

449 records 13/30 page Previous Next First page 上5页 1112131415 下5页 Last page